Global Stem Cell Market: Brief Overview

www.indiabusinessreports.
com
Global Stem Cell Market
Technology & Global Market Opportunity
Sector: Pharma / Healthcare Services
May 2014
Index
What are Stem Cells? 3
Types of Stem Cells and their Relative Merits 8
Status of Stem Cell R&D 16
Global Stem Cell Market Size 23
Leading Global Stem Cell Companies 30
Indian Stem Cell Companies 42
Deals in Stem Cell Space 45
www.indiabusinessreports.com 2 Global Stem Cell Market
What are Stem Cells?
www.indiabusinessreports.com Global Stem Cell Market
Stem Cell Definition
Stem cells are fundamental, basic, or undifferentiated cell of a multi-
cellular organism. They are capable of being transformed or grow into
indefinitely manifold cells of the same type, and from which, other kinds
of cell can be grown, by differentiation
Stem cells are at the center of a new field of science called Regenerative
Medicine.
Since stem cells can become a bone, muscle, cartilage and other
specialized types of cells, they have the potential to treat many
diseases, including Parkinson's, Alzheimer's, diabetes and cancer.
They may also be used to regenerate organs / skin, reducing the need for organ
transplants and related surgeries.
Types of Stem Cells
There are three broad categories of stem cells
Embryonic stem cells
Embryonic stem cells include those found within the embryo, the fetus or the
umbilical cord blood. Depending upon when they are harvested, embryonic
stem cells can give rise to just about any cell in the human body.
Adult / Tissue stem cells
Adult stem cells can be found in infants, children and adults. They reside in
already developed tissues such as those of the heart, brain and kidney. They
usually give rise to cells within their resident organs.
Induced pluripotent stem cells (IPSC)
These stem cells are adult, differentiated cells that have been experimentally
"reprogrammed" into a stem cell-like state.
Why Interest in Stem Cells
Increase understanding of how diseases occur
By watching stem cells mature into cells that eventually become bones, heart
muscle, nerve cells, and other organs and tissue, researchers and doctors will
have better understanding how a variety of diseases and conditions develop.
They have the ability to generate healthy cells to replace diseased cells
(regenerative medicine)
Researchers believe that they can train stem cells into becoming specific cells
so that those specialized cells can be used to regenerate and repair diseased
or damaged tissues in people.
Test new drugs for safety and effectiveness.
Before using new drugs in people, researchers could use stem cells to test the
safety and quality of investigational drugs.
For instance, nerve cells could be generated in order to test a new drug for a
nerve disease. Tests could show whether the new drug had any effect on the
cells and whether the cells were harmed.
Stem Cell Market Business Segmentation
Stem cell market can be segmented in four segments
Stem Cell Products
Adult stem cell, cord blood cells, human embryonic cells and other
Stem Cell Services
Stem cell banking, stem cell acquisition and testing, drug discovery and target
identification, isolation / characterisation services, and molecular biology
Stem Cell Technologies
Stem cell production, cryopreservation, expansion and sub-culture
Stem Cell Applications
Regenerative medicine neurological disorders, orthopedics, cancer
hematological disorder, incontinence, and drug development
Type of Stem Cells and Their Relative Merits
Popular Sources of Stem Cells
11%
33%
5%
5%
6%
11%
17%
6%
6%
Cell Type
Adipose
Bone Marrow
Embryonic
Epithelial
Fibroblasts
Source: www.seekingalpha.com
Type of Stem Cells and Their Current Uses Snap Shot
Type Source Their
capability
Current
researches
Clinic
readiness?
Advantages Limitations
Embryoni
c Stem
Cells
Early stage
embryo called
a blastocyst
Make all the
different
types of cells
in our body
Understanding how
our bodies develop
from a fertilized
egg; Investigating
how to produce
different types of
specialised cell
The first clinical
trials are now
beginning,
focussed on
treating eye
disorders; these
are early stage
safety trials
Can produce all the
different types of
cells in the body .
Can self-renew
(copy themselves)
almost forever, so
large supplies can
be made
Still learning how
to fully control
differentiation of
these cells. Some
concerns on
ethical or religious
grounds
Tissue
stem cells
(e.g. skin,
blood)
Tissues of the
adult body
Make only the
types of cells
that belong in
their own
tissue, e.g.
skin stem cells
make only
types of skin
cells, they do
not make
brain or blood
cells
Understanding how
adult tissues are
made and
maintained
Improving our
understanding of
diseases affecting
adult tissues,
including cancer
Skin and blood
stem cells have
been in use for a
number of years
for skin grafts
and bone
marrow
transplants
Already partly
specialised, which
can make it more
straightforward to
obtain the
particular
specialised cell
type required
How to multiply,
control and use
different types of
tissue stem cells.
Treatments for
blood diseases,
severe burns and
some types of
corneal damage
have been
proven; no other
treatments are
yet proven.
Type of Stem Cells and Their Uses Snap Shot
Type Source Their
capability
Current
researches
Clinic readiness? Advantages Limitations
Umbilical
Cord
Blood
StemCells
The umbilical
cord after the
birth of a
baby
Make the
different
types of cells
found in the
blood
Understanding
how blood stem
cells work
Mainly used to treat
children with blood
disorders, primarily
leukaemia; although
adults can
sometimes be
treated, this is
limited because only
a small number of
stem cells can be
obtained from a
cord
Can be frozen
and stored
Need to know how to
multiply cord blood stem
cells. Only proven uses are
for blood disorders; studies
suggesting these cells can
be used to make non-
blood-related types of cells
have not been widely
reproduced Cord blood
must be matched to the
patient to avoid rejection.
Mesen-
chymal
stem cells
(a type of
tissue
stem cell)
Bone marrow Make cells of
the skeletal
tissues: bone,
cartilage, fat
Support blood
stem cells to
make new
blood cells
Understanding
how these cells
contribute to
making and
maintaining
tissues
Clinical trials are
underway for
cartilage & bone
repair, for aiding
repair of blood
vessels after heart
attacks, and for
other unrelated
treatment
Already partly
specialised,
which can
make it more
straightforwa
rd to obtain
the particular
specialised
cell type
required
How to multiply, control
and use different types of
tissue stem cells.
Treatments for blood
diseases, severe burns and
some types of corneal
damage have been proven;
no other treatments are
yet proven.
Type of Stem Cells and Their Uses Snap Shot
Type Source Their
capability
Current
researches
Clinic readiness? Advantages Limitations
Induced
Pluripotent
stemcells
(iPS cells)
Made in the
lab from
specialized
adult cells,
for example
skin cells
Behave very
like
embryonic
stem cells
make all types
of cells in the
body
Can be made
from patients
and used to
produce cells
that act as a
model disease
in the
laboratory for
studying
diseases and
testing new
drugs
Not yet Could provide
patient-
specific
treatment
Not yet established how
reprogramming works .
Properties of cells need
further comparison with
embryonic stem cells As
with ES cells, we are still
learning how to fully
control these cells to
ensure they make the cells
we want in a way that will
be safe for clinical use
Diseases Curable by Cord Blood Stem Cells
Cancer Blood Disorders Immune Disorders Metabolic Disorders
1. Acute Leukemia
2. Chronic Leukemia
3. High-Risk Solid
Tumors
4. Hodgkin & Non-
Hodgkin
Lymphoma (types
of blood cancers)
5. Myelodysplastic
Syndromes *
1. Aplastic Anemia
2. Beta Thalassemia
3. Diamond-Blackfan
Anemia
4. Fanconi Anemia#
5. Sickle Cell Disease
1. Chronic
Granulomatous@
Disease
2. Hystiocytic Disorders$
3. Leukocyte Adhesion
Deficiency%
4. Severe Combined
Immunodeficiency
Diseases
5. Wiskott-Aldrich
Syndrome^
1. Krabbe Disease&
2. Hurler Syndrome+
3. Metachromatic
Leukodystrophy
4. Sanfilippo Syndrome
* Syndromes involving ineffective production of the myeloid class of blood cells. Patients with MDS can develop severe anemia and require
blood transfusions
# A genetic defect in a cluster of proteins
@ A genetic disorder in which certain immune system cells are unable to kill some types of bacteria and fungi
$ Histiocytic disorders are a group of diseases that occur when there is an over-production of white blood cells known as histiocytes that can
lead to organ damage and tumor formation
% A rare autosomal recessive disorder characterized by immunodeficiency resulting in recurrent infections
^ WiskottAldrich syndrome is a rare X-linked recessive disease characterized by eczema, thrombocytopenia, immune deficiency, and bloody
diarrhea
& Krabbe disease is a rare, often fatal degenerative disorder that affects the myelin sheath of the nervous system.
+ Hurler syndrome is a genetic disorder due to a deficiency of alpha-L iduronidase, an enzyme responsible for the degradation of
mucopolysaccharides in lysosomes
Hurler syndrome is a genetic disorder due to a deficiency of alpha-L iduronidase, an enzyme responsible for the degradation of
mucopolysaccharides in lysosomes
Diseases Curable by Adult Stem Cells
Cancer Cancer Auto-Immune
Disorders
Anemias/Blood
Conditions
1. Brain Cancer
2. Retinoblastoma
3. Ovarian Cancer
4. Skin Cancer:
Merkel Cell
Carcinoma
5. Testicular Cancer
6. Tumors abdominal
organs Lymphoma
7. Non-Hodgkins
lymphoma
8. Hodgkins
Lymphoma
9. Acute
Lymphoblastic
Leukemia
10. Acute
Myelogenous
Leukemia
11. Juvenile
Myelomonocytic
Leukemia
12. Cancer of the lymph
nodes
13. Multiple Myeloma
14. Myelodysplasia
15. Breast Cancer
16. Neuroblastoma
17. Renal Cell Carcinoma
18. Various Solid Tumors
19. Soft Tissue Sarcoma
20. Waldenstrom's
macroglobulinemia
21. Hemophagocytic
lymphohistiocytosis
22. POEMS syndrome
1. Multiple Sclerosis
2. Crohn's Disease
3. Scleromyxedema
4. Scleroderma
5. Rheumatoid Arthritis
6. Juvenile Arthritis
7. Systemic Lupus
8. Polychondritis
9. Sjogren's Syndrome
10. Behcet's Disease
11. Myasthenia
12. Autoimmune
Cytopenia
13. Systemic vasculitis
14. Alopecia universalis
1. Sickle cell anemia
2. Sideroblastic anemia
3. Aplastic Anemia
4. Amegakaryocytic
Thrombocytopenia
5. Chronic Epstein-Barr
Infection
6. Fanconi's Anemia
7. Diamond Blackfan
Anemia
8. Thalassemia Major
9. Red cell aplasia
10. Primary
Amyloidosisme
Diseases Curable by Adult Stem Cells
Wounds/Injuries Neural Degenerative
Diseases/Injuries
Immunodeficiencies Other Metabolic
Disorders
1. Limb gangrene
2. Surface wound
healing
3. Jawbone
replacement
4. Skull bone repair
1. Parkinson's disease
2. Spinal cord injury
3. Stroke damage
1. X-Linked hyper
immunoglobuline-M
Syndrome
2. Severe Combined
Immunodeficiency
Syndrome
3. X-linked
lymphoproliferative
syndrome
1. Osteogenesis
imperfecta
2. Sandhoff disease
3. Hurler's syndrome
4. Krabbe Leukodystrophy
5. Osteopetrosis
6. Cerebral X-linked
adrenoleukodystrophy
Other diseases that can be cured are repairing heart damage and corneal regeneration
Status of Stem Cell R&D
Stem Cell therapies At the Cusp of Emerging
The cell therapy sector, is currently engaged in over 1,900 clinical
trials around the world. This includes more than 300 clinical trials
being sponsored by approximately 250 companies developing
commercial products for almost every imaginable disease or
condition.
In 2012, the sector garnered over $900 million in investment
from private investors and public markets, and over $300 million
from grant sources aggregating an approximate $1.2 billion in
investment.
Global Pharma investing in Regenerative Med
100% of the companies interviewed in ARMs Pharma and Biotech Survey are investing in
regenerative medicine
Key therapeutic opportunities
Industry sees Wound and Burns as the biggest opportunity area, followed by
neuro, autoimmune, ocular and cardio vascular diseases
Stem cell based new drug candidates the key focus
69% of the companies have invested in cellular-based regenerative medicine products
Over 50 late stage trials
Cancer, Musculo skeletal , and non healing wounds would see a spate of new products
Korea leads Asia in stem cell research pipeline
Global Stem Cell Market Size
Over 100 cell therapy products in the market currently
Wound care products are a large share
Non healing wounds, and skin are almost half the products
The first of these products, Apligraf, was brought to market in 1998.
In the past five years there have been 12 approvals: United States (six), Europe (one), Canada
(one), New Zealand (one), and South Korea (three).
Source: ARM
Small market size currently; immense potential ahead
In 2013, Regenerative Medicines surpassed $1 billion in annual
revenue, with over 160,000 patients receiving treatment
In addition, over 60,000 stem cell transplants annually
performed worldwide for the treatment of oncology and blood-
based disorders
The potential savings from regenerative medicine treatments
for the United States alonein terms of reducing the direct costs
associated with chronic diseases have been estimated at
approximately $250 billion a year.
Stem Cell Business Opportunity Global
According to Axis Research Mind, global stem cell market was estimated to
be $ 21 billion in 2010
Estimated to reach $ 60 billion by 2015
North America constitutes 60% of the global market, however its the Asian
market which is growing faster
Asian markets are estimated to grow at 25% CAGR during the period 2010-
2015
In the Asian region, Japan, China, Singapore, Korea and Australia are the
major hubs for stem cell research
Umbilical Cord Blood Business Opportunity Global
Allied Market Research estimates that the global umbilical cord blood
stem cell market is forecasted to reach market value over $11.5 billion in
2014 from $ 6.5 billion in 2012
Developments and approvals for novel cord blood stem cells therapies is
expected to drive the market growth.
The market is expected to reach revenue of $56.4 billion by 2020, growing
at CAGR of 33.4%during 2013 to 2020.
The stem cell storage service market was valued at $7.4 billion in 2013
Indian stem cell banking market
Cord Blood Stem Cell Banking has emerged as new opportunity of healthcare
services provider in Indian market. The market is still in nascent stage of
development and valued around US$ 60 Million in 2013 and further expected
to surpass US$ 400 Million by 2018. The current cord blood stem cell
preservation level for new born baby is below 1% and hence there exists
immense opportunity for cord blood stem cell preservation service providers
to grow exponentially in coming years.
Key Global Companies in Stem Cell Market
A vibrant market
They are developing:
cell-based therapies, small
molecules, biologics, tissue-
engineered cells and materials and
implantable devices
drug discovery or toxicity testing tools
as well as clinical tools, bioprocessing
tools and platforms that include
equipment, consumables, reagents
and storage systems
The field also incorporates a variety of
service companies specializing in
clinical trial
management, manufacturing, engine
ering and financing among others.
Alliance for Regenerative Medicine (ARM) estimates there are over 700 companies
with a regenerative medicine focus ranging from divisions of multinational
corporations to smaller organizations focused solely on the sector.
Listed Therapeutic Companies
www.indiabusinessreports.com 32 Global Stem Cells Market
Several listed stem cell companies. All are still in investment mode, with R&D spends
much higher than revenue Most of them have products in Phase II or later stages
Company Name Market Cap Revenue
(2013)
R&D Exp EBITDA Net IncomeEmployees Founded
1 Mesoblast Inc 1,460.1 32.6 40.1 -55.8 -57.7
76 2004
2 Osiris Therapeutics Inc 444.5 24.3 5.0 -2.8 -1.1
70 1992
3 Neuralstem, Inc., 355.2 0.1 7.1 -12.5 -19.8
15 1996
4 PluristemTherapeutics Inc 235.4 0.7 17.2 -22.2 -21.2
160 2001
5 Athersys, Inc. 225.3 2.4 20.5 -24.5 -30.7
56 1995
6 NeoStem, Inc 197.2 14.7 16.9 -36.8 -40.0
108 1980
7 Cytori Therapeutics, Inc 187.9 12.2 17.1 -30.7 -26.2
115 1996
8 Fibrocell Science, Inc 165.0 0.2 12.6 -30.5 -30.0
58 1995
9 TiGenix NV 161.5 5.9 15.0 22.1 -25.4
19 2000
10 Advanced Cell Technology 161.0 0.2 11.6 -29.7 -30.6
38
11 Invivo Therapeutics Holdings Corp 120.9 - 10.5 -19.0 -38.8 70 2005
12 StemCells, Inc 71.5 1.2 20.5 -28.6 -26.4
58 1988
13 Cytomedix, Inc. 68.1 11.6 3.8 -18.1 -20.2
40 1987
Source: Stem Cell Stock Index, finance.yahoo.com
Mesoblast( Aus): Worlds leading stem cell company
Set up in 2004. Did an IPO in Dec04. Raised $175mn in Mar13, via a private placement
Acquired the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics in
Oct13. Acquired US company Angioblast in 2010 at A$250mn valuation
Has 110 patents now
Stem Cells working with 4 types
Mesenchymal Precursor Cell; Cultureexpanded Mesenchymal Stem Cells; Dental Pulp Stem Cells; Expanded
Hematopoietic Stem Cells
Therapeutic areas
10 leads across 4 areas: Inflammatory, Spine, Cardio and Onco
Phase III CHF (n=1700) (partnership with Teva)
Phase III spinal fusion (expected 2014)
Phase III Prochymal in GvHD and Crohns Disease
Degenerative Disc Disease (expected PIII in 2014)
Phase II type II diabetes
Phase II Rheumatoid Arthritis
Phase II Macular degeneration
Alliances
Teva: To commercialise adult cells for degenerative conditions of the cardio and CNS
Lonza: To ensure commercial scale-up, COGS reduction and clinical manufacturing
JCR Pharmaceuticals (Japan): For use of MSCs in Graft versus Host disease programmes in children and adults
Osiris, USA
Founded in 1992, did IPO in 2006
Developed the worlds first approved stem cell drug, remestemcel-L (brand name
Prochymal) for graft versus host disease, which got approval in Canada
Sold Prochymal to Mesoblast in 2013 in a deal worth $100mn + royalties.
Sold Biosurgery product Osteocel to Nuvasive, Inc. in 2008 for ~$80 million
Now focussed on Biosurgery: wound care, orthopedic and sports medicine markets.
Has 3 commercial products, focussed on developing revenues. In 2014, for the first time in
the companys history, commercial investments will exceed R&D investments
From inception in December 1992 through December 31, 2013, Osiris has incurred
aggregate research and development costs of approximately $436 million
Stem Cells
Was using Adult Bone Marrow cells for Prochymal
Current products based on human tissue
Curent Therapeutic areas
Grafix: Diabetic foot ulcers and burns
Ovation: Wound healing
Ovation OS: Bone repair
Cartiform: Cartilage restoration
Neuralstem, USA: Leader in Neural Stem Cell Science
Founded in 1996, listed in 2006
Raised $20mn in Jan14, has warrants outstanding for a similar amount
Neuralstemis growing regionally specific cells that are already suited to the task prescribed
to them once transplanted into the CNS
15 U.S. patents re-affirmed worldwide technology and product; 9 pending
Stem Cells
Patented technology for isolation and expansion of Neural stem cells
Curent Therapeutic areas
Amyotrophic Lateral Sclerosis (ALS): Phase II trials commenced in Sep13
Ischemic Stroke: Phase II trials commenced in Dec13
Spinal Cord Injury: Phase I trials expected to commence in Apr14
Multiple Sclerosis, Optic Neuritis, Alzheimers Disease: In pre-clinical phase
Pluristem, Isreal: Leader in placenta based cell science
Founded in 2001, listed in 2007
28 granted patents and over 100 pending applications globally
Stem Cells
Utilizes PLacental eXpanded (PLX) mesenchymal like adherent stromal cells Treatment of a
variety of inflammatory and ischemic conditions
Therapeutic areas has around 20 products in its pipeline spanning
Cardio 5 products
Ortho 2 products
Pulmonary 2 products
Womens health 1 product
Hematology 4 products
CNS 3 products
Alliances
With United Therapeutics, Inc for a Pulmonary Hypertension product. Has already
received $7mn upfront payment, and in line to receive $55mn milestone payments
With CHA Bio & Diostech, a Korean company, for CLI trials and 50:50 JV in S Korea
Athersys, USA
Founded in 1996, went public through reverse merger in 2007 and raised $ 65 mn
Funded by firms like Radius Ventures, OrbiMed Advisors, MPM BioEquities and others
Over 130 issued patents (including RM and other areas)
Stem Cells
Developing MultiStem, a patented, adult-derived off-the-shelf stem cell product platform
Therapeutic areas - multiple disease indications in the areas of
inflammatory and immune
neurological
cardiovascular disease.
Alliances
Development & commercialisation partnerships with Bristol-Myers Squibb (BMS), Angiotech
Pharma and Pfizer
Several promising unlisted companies
Organogenesis, USA: Largest by revenue
With $100mn revenue in 2011, largest
regenerative company in the world
Founded in 1985, listed in 1986, went
private in 2002
Got FDA approvaal for flagship product
Apligraf in 1998, ahead of its time
Acquired Dermagraft from Shire Plc in
Jan14 for staged payments upto $300mn
Stem Cells
Apligraf is a matrix of cow
collagen, human fibroblasts and
keratinocyte stem cells (from discarded
circumcisions)
Therapeutic Areas
Wound healing (Apligraf)
Oral regeneration (Gintuit)
Gamida (Isreal): Leader in stem cell
expansion tech
Has developed a large number of platform
technologies to expand functional cell
populations
Backed by strategics and venture funds:
Elbit Imaging, Clal Biotechnology
Industries, Israel Healthcare Venture, Teva
Pharma, Amgen, Denali Ventures and Auriga
Ventures
Stem Cells
UCB stem cells
Therapeutic Areas
Blood cancer, solid tumours, autoimmune
and metabolic disorders
Its lead product StemEx is in Phase III for
treatment for bone marrow transplant for
blood cancer, and will be launched soon
Stem Cell Banks
China Cord Blood Corporation: Largest Chinese Stem Cell Bank
Chinas leading provider of cord blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services
Listed on NYSE in 2009, when it raised $20mn. Leading US PE fund KKR invested $65mn in
CCBC in Apr12
Business profile
Accumulated subscriber base reached 359,487 by Dec13
Under PRC government regulations, only one licensed cord blood bank is permitted to
operate in each licensed region and only seven licenses have been authorized as of today
The only operator with multiple licenses, with access to 4* of the 7 authorized licenses. It has
its own centres in Beijing, Guangdong, and Zhejiang; and holds equity in another bank
Stem Cell Banks
Cordlife Group, Singapore
The first cord blood bank to be set up in Singapore (May 2001)
Listed on Singapore Exchange Main Board on 29 March 2012
Has done aggressive investments recently. The Group acquired 10% equity in China Cord
Blood Corporation, one of the top operators in China. It also accquired 32% stake in StemLife
Bhd, Malaysia. It also acquired parts of Asian business of Australias Cordlife Limited.
Business profile
Owns and operates full processing and cryopreservation storage facilities across Asia, namely
in Singapore, Hong Kong, India, Indonesia and The Philippines
Service Companies
Hope Medical Group, China
Group of five hospitals in China certified by The Chinese Ministry of Health to provide adult
stem cell and Cancer immunotherapy treatments for local and global patients.
The Hospitals are
Wuxi Peoples Hospital, Jiangsu: 1870 beds. It is also Ministry of Health stem cell technical training base
Marys Orthopedic Hospital, Beijing: 260 beds, focusses on stem cell treatment in bone & cartilage injuries; bone
coloboma & bone non union; ischemic necrosis of femoral head; osteoarthritis; Erbs disease; neck, back pain caused
by Intervertebral Disc Degeneration etc.
Beijing Zhenguo Tumor Rehabilitation Hospital: 300 beds, focusses on cancer and tumour
Guangzhou Cancer Center: 1000 beds
Hengyang Stem cell and cancer center: 1500 beds, offers Hemopoietic stem cell transplantation
Leading Indian Companies
Key Indian Players and their Focus in Sub-Sectors of Stem
Cell Segment
Company Profile Banking Research Product
Reliance
Life
Sciences
It has in-house capabilities in
research, development,
commercial manufacturing, sales
& marketing. The company is
developing products in the
domain of regenerative medicine
(stem cell therapies, tissue
engineered products, stem cell
enriched repository services,
assisted reproduction)
Cord Blood
Repository offering
both public and
family banking
services
Regenerative medicine
range of novel
autologus and
allogenic cell therapies
and tissue engineered
products
ReliNethra:
Autologus limbal
stem cell composite
graft
CardioRel:
Autologus
cardiomyocytes
LifeCell LifeCell is Indias first & largest
private stem cell bank and stem
cells solutions provider. The
company has a technological
collaboration with CRYO-CELL
International Inc. the worlds
first and largest stem cell bank
Umbilical cord
blood & cord
tissue; menstrual
blood cell banking
TRICell Therapeutics:
Research in autologus
bone marrow for the
treatment of non
reconstructable critical
limb ischemia;
allogenic cord blood
infusion in patients
with Type I diabetes;
burns and wound
healing etc.
Key Indian Players and their Focus in Sub-Sectors of Stem
Cell Segment
Company Profile Banking Research Product
Cryobanks
India
Founded in 2006, the company is a
JV between Cryobanks
International USA and RJ Corp,
under the guidance of Dr. Naresh
Trehan (Medanta). Approved by US
FDA
Umbilical cord
blood stem cell
banking
Cryobanks is
conducting research
on the use of stem
cells for several
therapy areas like
Diabetes, Alzheimers,
Multiple Sclerosis,
Cariology etc.
Stempeutics The company is developing stem
cell based medicinal products, with
facilities in Bangalore, Manipal and
Malaysia. The company has an
alliance with Cipla for the
marketing of its products. Its first
product, for critical limb ischemia,
is set to be commercialised soon
Derived from
bone marrow
Stempeutics has 8
products in clinical
trials, in Phase I and II
stages. These are in
the area of Cardiology,
Diabetes, Osteo-
arthritis, Liver and
Critical Limb Ischemia
Stempeucel-CLI for
critical limb
ischemia is now set
for a Phase III trial
and a launch after
that soon
OCT
Therapies &
Research
OCT is currently working on its first
product: a WJ-MSC based approach
towards advanced would care. The
company has filed for patent, and is
currently doing animal trials
WJ-MSC Its first product is
currently in animal
tests. OCT aims to start
Phase 1 within a year
For mild to severe
burns, and chronic
ulcers. It is a topical
application
Deals: Acquistions / Funding / Partnerships
Acquisitions and mergers
When Acquirer Acquired Valuation ($mn) Key Assets
Apr'14 Neostem California Stem
Cell Inc
n.a Melapuldencel-T, which targets cancer initiating cells for melanoma, will
become NeoStem's most advanced product candidate. Will undergo
Phase III in 2014
Apr'14 Fate Therapeutics, Inc Verio Therapeutics
Inc
n.a Developing drug candidates targeting the activation of endogenous stem
cells
Mar'14 Intrexon Corporation Medistem, Inc n.a Pioneer in the development of Endometrial Regenerative Cells ("ERC" or
"ERCs"), universal donor adult-derived stem cells with properties
uniquely suited for therapeutic use with Intrexon's existing suite of
synthetic biology technologies
Jan14 Organogenesis Dermagraft from
Shire Plc
300 Shire Plc exited RM business it acquired in 2011 when it purchased
Advanced BioHealing. Organogenesis has $100mn+ revenue from
Apligraf, and gets another $70mn from this deal, consolidating its No 1
position in the US advanced wound care market.
Oct'13 StemCells, Inc. Patents from
Neurospheres
Holdings Ltd
n.a The portfolio broadly claims the manufacture and proliferation of purified
populations of human neural stem cells and their use as therapeutics and
as tools for drug discovery
Apr'13 Stem Cell Therapeutics
Corp
Trillium
Therapeutics Inc
Merger Immunotherapy and cancer stem cell research
Nov'12 Smith & Nephew plc Healthpoint
Biotherapeutic
782 Bioactive debridement, dermal repair and regeneration wound care
treatments
Jun'12 Royal DSM Kensey Nash 360 Biomedical equipment following advances in regenerative medicine and
tissue engineering
Apr'12 Shire PLC Pervasis
Therapeutics
200 Vascugel, a biodegradable implant containing human endothelial cells in
Phase II testing to prevent hemodialysis vascular access failure in
patients with end-stage renal disease (ESRD)
Feb'12 Cytomedix Inc Aldagen Inc 40 Regenerative therapies for wound care, inflammation and blood vessel
developmen
Jan'12 Mediware Information
Systems Inc
Transtem LLC. Software for managing the collection and transplantation of adult stem
cells for cellular therapy and medical research
Oct'11 NeoStem Inc Amorcyte n.a AMR-001, a stem cell treatment being evaluated for the treatment of
acute myocardial infarction
PE deals
When Investor Target Deal Size
($mn)
Country
Dec'13 Special Situations Funds, Ridgeback Capital,
Merlin Nexus, Sabby Capital, venBio, Opaleye
Management and HSMR Advisors.
Stem Cell Therapeutics
Corp
30 USA
Nov'13 Sheridan Legacy Group Progenicare n.a USA
Aug'13
Ballast Point Ventures and River Cities Capital
Funds TissueTech Inc. 10
USA
Jul'13 Wales Life Sciences Investment Fund ReNeuron 20 Wales
Feb'13
Helion Lifecell International Pvt
Ltd 7 India
Apr'12
KKR China Cord Blood Corp
65 China
Jul'11
Johnson & Johnson Development Corp.,
Sanderling Ventures and Asset Management Co.
Viacyte Inc
11 USA
Apr'11
Tactics II Stem Cell Ventures, Sam Zell's Equity
Group Investments LLC, Sixth Floor Investors LP
and G Force Investments LLC
Cellular Dynamics
International, Inc
30 USA
Apri'11
PBM Capital Group, L.P
GigaCyte
n.a USA
Disclaimer
www.indiabusinessreports.com Global Stem Cell Market 48
Copyright2014 India Business Reports
All rights reserved. No part of this publication may be reproduced or utilized, stored in a retrieval system, or transmitted in any form or
by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of India Business Reports
(IBR)
Legal Notices and Disclaimer
None of IBR, its partners, employees, affiliates, representatives or advisors make any representation or warranty, expressed or
implied, as to the accuracy or completeness of any of the information contained herein, including any opinion or any other written or
oral communication transmitted or made available. Each recipient of such information expressly disclaims any and all liability relating to
or resulting from the use of such information and communications by a recipient or any of its affiliates, advisors or representatives. In
particular, no representation or warranty is given as to the achievement or reasonableness of any future projections, estimates or
statements about the future prospects of any of the companies.
This document is for the use of the persons who receive it directly from IBR. Recipients agree that all of the information contained in it
is of a confidential nature, and that they will not, directly or indirectly, disclose any such information without the prior written consent
of IBR.
Confidentiality
In consideration of you receiving a copy of this document, you agree to keep confidential the contents of this document and shall
not, without the prior written approval India Business Reports (IBR) disclose to any person the whole or any part of the information
contained in, or associated with this document.
Thank You
reports@indiabusinessreports.com

Global Stem Cell Market: Brief Overview

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Global Stem Cell Market: Brief Overview

Uploaded by

Copyright:

Available Formats

www.indiabusinessreports.

You might also like